Association between the Cytotoxic T-Lymphocyte Antigen 4 +49G > A polymorphism and cancer risk: A meta-analysis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zheng, Jian ^a   Yu, Xiao ^a   Jiang, Lan ^a   Xiao, Mang ^b   Bai, Bing ^a   Lu, Jiachun ^c   Zhou, Yifeng ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN;

ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CHINESE; EPITHELIUM TUMOR; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; SKIN CANCER; SOLID TUMOR; BREAST TUMOR; ETHNIC GROUP; FEMALE; GENETIC PREDISPOSITION; GENETICS; LYMPHOCYTE ACTIVATION; MALE; META ANALYSIS; METABOLISM; NEOPLASM; RISK;

ANTIGENS, CD; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; NEOPLASMS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK;

EID: 77957261797     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-522     Document Type: Article

References (46)

1. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989, 143(8):2714-2722.
2. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991, 88(15):6575-6579. 10.1073/pnas.88.15.6575, 52129, 1650475.
3. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992, 176(6):1595-1604. 10.1084/jem.176.6.1595, 2119471, 1334116.
4. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992, 360(6401):266-268. 10.1038/360266a0, 1279442.
5. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993, 366(6450):76-79. 10.1038/366076a0, 7694153.
6. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993, 262(5135):907-909. 10.1126/science.7694362, 7694362.
7. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993, 262(5135):905-907. 10.1126/science.7694361, 7694361.
8. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993, 259(5093):368-370. 10.1126/science.7678351, 7678351.
9. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002, 3(11):1097-1101. 10.1038/ni846, 12368911.
10. Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, Sansom DM. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol 2002, 32(10):2888-2896. 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F, 12355442.
11. Schneider H, Valk E, Leung R, Rudd CE. CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS One 2008, 3(12):e3842. 10.1371/journal.pone.0003842, 2585791, 19052636.
12. Carlow DA, Kerbel RS, Elliott BE. Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. J Natl Cancer Inst 1989, 81(10):759-767. 10.1093/jnci/81.10.759, 2654405.
13. Elliott BE, Carlow DA, Rodricks AM, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 1989, 53:181-245. full_text, 2678947.
14. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996, 5(7):1075-1080. 10.1093/hmg/5.7.1075, 8817351.
15. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991, 147(3):1037-1044.
16. Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, Shi Y, Yao J, Guo Y, Yu D, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008, 68(17):7025-7034. 10.1158/0008-5472.CAN-08-0806, 18757416.
17. Wang L, Li D, Fu Z, Li H, Jiang W. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 2007, 7:173. 10.1186/1471-2407-7-173, 2001196, 17825114.
18. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000, 165(11):6606-6611.
19. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002, 54(1):1-8. 10.1007/s00251-002-0429-9, 11976786.
20. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955, 19(4):251-253. 10.1111/j.1469-1809.1955.tb01348.x, 14388528.
21. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127(9):820-826.
22. Petitti DB. Of babies and bathwater. Am J Epidemiol 1994, 140(9):779-782.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 2127453, 9310563.
24. Chuang WY, Strobel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Muller-Hermelink HK, Marx A. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 2005, 58(4):644-648. 10.1002/ana.20577, 16178018.
25. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 2007, 22(12):2283-2287. 10.1111/j.1440-1746.2007.04862.x, 18031393.
26. Pavkovic M, Georgievski B, Cevreska L, Spiroski M, Efremov DG. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol 2003, 72(2):147-149. 10.1002/ajh.10278, 12555221.
27. Solerio E, Tappero G, Iannace L, Matullo G, Ayoubi M, Parziale A, Cicilano M, Sansoe G, Framarin L, Vineis P, et al. CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer. Dig Liver Dis 2005, 37(3):170-175. 10.1016/j.dld.2004.10.009, 15888281.
28. Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, Nelson HH. CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res 2009, 69(15):6158-6163. 10.1158/0008-5472.CAN-09-0415, 2928067, 19622768.
29. Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Dehaghani AS. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004, 86(1):1-7. 10.1023/B:BREA.0000032918.89120.8e, 15218356.
30. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, Garrido F, Ruiz-Cabello F. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007, 68(8):698-704. 10.1016/j.humimm.2007.05.002, 17678726.
31. Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 2008, 35(4-5):317-321. 10.1111/j.1744-313X.2008.00782.x, 18680513.
32. Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, Gu X, Zhao YP, Dou TH, Gao CF. CTLA-4 +49A > G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. Int J Colorectal Dis 2010, 25(1):39-45. 10.1007/s00384-009-0806-z, 19787358.
33. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, Wang TE, Cheng AL, Wu MS. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006, 24(21):3483-3489. 10.1200/JCO.2005.05.5434, 16849765.
34. Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, Noli A, Gabbas A. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004, 76(1):14-18. 10.1002/ajh.20045, 15114591.
35. Piras G, Monne M, Uras A, Palmas A, Murineddu M, Arru L, Bianchi A, Calvisi A, Curreli L, Gaviano E, et al. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma. Br J Haematol 2005, 129(6):784-790. 10.1111/j.1365-2141.2005.05525.x, 15953005.
36. Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T, Urbaniak-Kujda D, Kuliczkowski K, Wolowiec D, Jedynak A, Frydecka I. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Hum Immunol 2008, 69(3):193-201. 10.1016/j.humimm.2008.01.014, 18396212.
37. Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, Xu C. Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 2010, 37(1):515-520. 10.1007/s11033-009-9705-1, 19688278.
38. Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, Kumar R. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?. Cancer Immunol Immunother 2009, 2776942, 19672595.
39. Xiao M, Qi F, Chen X, Luo Z, Zhang L, Zheng C, Hu S, Jiang X, Zhou M, Tang J. Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population. Int J Immunogenet 2010, 37(1):27-32. 10.1111/j.1744-313X.2009.00888.x, 19922464.
40. Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, Lin M, Wang PT, Huang WC, Chen TC, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007, 28(6):1237-1240. 10.1093/carcin/bgm043, 17341658.
41. Wong YK, Chang KW, Cheng CY, Liu CJ. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 2006, 35(1):51-54. 10.1111/j.1600-0714.2005.00377.x, 16393254.
42. Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010, 71(1):83-87. 10.1016/j.humimm.2009.09.353, 19778566.
43. Buonavista N, Balzano C, Pontarotti P, Le Paslier D, Golstein P. Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics 1992, 13(3):856-861. 10.1016/0888-7543(92)90169-S, 1322357.
44. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993, 11:191-212.
45. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med 1998, 188(10):1849-1857. 10.1084/jem.188.10.1849, 2212416, 9815262.
46. Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 2008, 8(2):153-160. 10.1038/nri2253, 18219311.